FY2025 Q4 Earnings Announcement Embarking on a New Era:
From Transformation to Growth Acceleration

from the beginning

FY2025 Q4 Earnings Announcement Embarking on a New Era: From Transformation to Growth Acceleration

Important Notice

Opening Remarks

Business Highlights

Delivered Solid FY2025 Results & Excellent Pipeline Progress, Setting us up for a Period of Major Product Launches

Poised to Launch 3 Transformative Medicines in the Next 12 Months Setting Takeda on a New Growth Trajectory

3 Near-term Launches are Just the Beginning; 5 Additional Highly Innovative NMEs in Late-Stage Pipeline

New Organizational Structure & Executive Leadership Team to Fuel Speed, Competitiveness and Future Growth

Proposed Board of Directors Rich in Diversity & Experience, With Relevant Expertise in a New Era for Takeda

Embarking on a New Era Defined by Two Growth Horizons, Bridging from Transformation to Acceleration

Financial Highlights

Delivered Solid FY2025 Results with OPEX Savings Limiting the Profit Impact of VYVANSE Generic Erosion

Achieved Latest FY2025 Management Guidance

Growth & Launch Products +4.5% at CER in FY2025

Growth & Launch Products Partially Mitigated Substantial Revenue Impact from VYVANSE Loss of Exclusivity

OPEX Savings through Efficiency Program Enabled us to Protect Core Operating Profit While Investing for Growth

Reported Operating Profit Benefitted from Step-down in Amortization and Restructuring Expenses

Adjusted Free Cash Flow of JPY 684.5B in-line with Forecast; Ended Fiscal Year with Strong Cash Balance

Plan to Repay FY2026 Debt Maturities Predominantly through Cash on-Hand & Free Cash Flow

Strong Track Record of Delivering OPEX Savings; New Transformation Program will Further Unlock Efficiencies

FY2026 Outlook for a Year of Growth Investment

Revenue Guidance Reflects Mature Portfolio Headwinds in a Year that we Pivot to New Launches

Year of Growth Investment Funded by Transformation Program

Reported Operating Profit Reflects end of VYVANSE Amortization Period Offset by Restructuring Costs

Committed to Strict Financial Discipline Through Our Two Growth Horizons

Committed to Growth & Shareholder Returns

Pipeline Highlights

Poised to Launch 3 Transformative Medicines in the Next 12 Months Setting Takeda on a New Growth Trajectory

Zasocitinib: Poised to be a Leading Oral Treatment Option for Patients with Psoriasis - Significantly Expanding the Oral Market

Zasocitinib Led to Greater Proportions of Patients Achieving PASI 90 than Apremilast or Placebo as Early as Week 4

Rapid Skin Clearance as Early as Week 4 with Zasocitinib

Zasocitinib Demonstrated Superior Improvement in DLQI Versus Apremilast or Placebo as Early as Week 4

Excellent Durability: >90% of Patients Continuing Zasocitinib at Week 40 Maintained sPGA 0/1, PASI 75 and PASI 90 Through Week 60

Zasocitinib: Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Delivering Our Late-Stage Programs that have the Potential to Transform Lives and Generate Significant Value

Delivering Our Late-Stage Programs that have the Potential to Transform Lives and Generate Significant Value

Outlook for Key Assets in FY26 and FY27

Closing Remarks

Embarking on a New Era Defined by Two Growth Horizons, Bridging from Transformation to Acceleration

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

39

Q&A SESSION2

39

Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

20

Q&A SESSION4

20

Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

APPENDIX